✦ LIBER ✦

Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial

✍ Scribed by Tony SK MOK; Te-Chun HSIA; Chun-Ming TSAI; Kenneth TSANG; Gee-Chen CHANG; John Wen-Cheng CHANG; Sirisinha THITIYA; Virote SRIURANPONG; Sumitra THONGPRASERT; Daniel TT CHUA; Nicola MOORE; Christian MANEGOLD

Book ID: 114829865
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 202 KB
Volume: 7
Category: Article
ISSN: 1743-7555
DOI: 10.1111/j.1743-7563.2011.01397.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6509 ORAL Management of hypertension (HT

6509 ORAL Management of hypertension (HTN) in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line cisplatin and gemcitabine with bevacizumab or placebo – results from randomised phase III trial BO17704

✍ Bennouna, J.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

PCN14 AN INDIRECT COMPARISON OF THE EFFI

PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

✍ S Walzer; J de Castro Carpeño; A Vergnenegre; C Chouaid; D Heigener; HG Bischoff 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

6503 ORAL Efficacy and safety results fr

6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)

✍ Manegold, C.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

9091 POSTER Quality of Life Assesment in

9091 POSTER Quality of Life Assesment in Patients With Non-Small Cell Lung Cancer Patients Who Have or Have Not Received Second Line Chemotherapy

✍ Yalcin, B.; Suna, N.; Dogan, M.; Urun, Y.; Özdemir, N.; Gonullu, U.; Zengin, N.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 39 KB

9170 Safety and efficacy of first-line b

9170 Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390)

✍ Garrido, P.; Thatcher, N.; Crino, L.; Dansin, E.; Laskin, J.; Pavlakis, N.; Tsai 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

PCN82 COST COMPARISON OF BEVACIZUMAB PLU

PCN82 COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY – AN UPDATED ANALYSIS

✍ HG Bischoff; A Hermes; DF Heigener; S Cesaro-Tadic; S Walzer; M Nuijten 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB